ABT Aqua Bio Technology

Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approved

Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approved

Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approved

Reference is made to the stock exchange announcement of regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. We have today received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 18 products are expected in January 2021, while the last 3 products are expected to be approved during Q1 2021. Balance & Vitality will be a complete skincare series with products in all categories.

The tests were performed at Eurofins, which is the world's largest in testing food, environment, medicine and cosmetics and has 800 laboratories in more than 50 different countries.

ABT expects the Balance & Vitality product series to be ready for distribution and sale in the first half of 2021.

For further information, please contact Espen Kvale, CEO, telephone  092.

Aqua Bio Technology (ABT) is developing and commercializing sustainable biotechnology for use in skin care products. ABT's cosmetics ingredients are effective and they provide the cosmetics industry with natural alternatives to traditional ingredients. ABT is also marketing and distributing natural skin care products developed by partners towards consumers and professional users.  ABT's focus on commercialization and development of natural ingredients and natural skin care products has been, and will continue to be, an important part of the company's strategy going forward. Aqua Bio Technology is listed on Euronext Expand.



EN
14/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aqua Bio Technology

 PRESS RELEASE

Aqua Bio Technology ASA: Safety studies of 6 products from the product...

Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approved Aqua Bio Technology ASA: Safety studies of 6 products from the product series Balance & Vitality completed and approvedReference is made to the stock exchange announcement of regarding ongoing safety studies for the Nordic Beauty and Balance & Vitality product series. We have today received confirmation that the first 6 products from Balance & Vitality have passed the safety studies that the EU requires to be carried out before commercialization. The results for further 1...

 PRESS RELEASE

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produkts...

Aqua Bio Technology ASA: Sikkerhetsstudier av 6 produkter fra produktserien Balance & Vitality fullført og godkjent Det vises til børsmelding av vedrørende pågående sikkerhetsstudier for produktseriene Nordic Beauty og Balance & Vitality. ABT har mottatt bekreftelse på at de 6 første produktene fra Balance & Vitality serien har passert sikkerhetsstudier som EU krever gjennomført før kommersialisering. Resultatene for ytterligere 18 produkter forventes i løpet av januar i 2021, mens de siste 3 produktene som kompletterer serien forventes godkjent i løpet av Q1. Balance & Vitality vil være e...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with...

Aqua Bio Technology ASA: Hydrafacial has entered into partnership with Restorsea - Conversion Lab launches Veritas MD platform Restorsea's commercialization of Aqua Bio Technologies ASA's hatching fluid ingredient (Aquabeautine XL) continues. As mentioned in the commercial update on November 26, 2020, Restorsea has recently entered into two license agreements with two partners in addition to the license agreement with NASDAQ-listed Conversion Labs. In connection with Hydrafacial`s merger with Vesper Healthcare and the contemplated listing on (NASDAQ), Restorsea is presented as . In Q3 20...

 PRESS RELEASE

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restors...

Aqua Bio Technology ASA: Hydrafacial har inngått samarbeid med Restorsea – Conversion Lab lanserer Veritas MD plattform Restorseas kommersialisering av Aqua Bio Technologys ASAs klekkeveskeingrediens (Aquabeautine XL) fortsetter. Som nevnt i kommersiell oppdatering 26. november 2020, har Restorsea nylig inngått to lisensavtaler med to partnere i tillegg til lisensavtalen med NASDAQ-noterte Conversion Labs. I forbindelse med Hydrafacial`s fusjon med Vesper Healthcare og den planlagte noteringen på (NASDAQ), presenteres Restorsea som . Hydrafacial opplyser at selskapet per Q3 2020 har utpl...

 PRESS RELEASE

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - dis...

Aqua Bio Technology ASA: Acquisition of Moana Skincare completed - distribution agreement for New Zealand and Australia close Reference is made to where it is informed that Aqua Bio Technology ASA (ABT) is acquiring all rights to Moana Skincare . This acquisition has now been completed and in the near future ABT expects to enter into a three-year agreement for the distribution of Moana products in New Zealand and Australia. Moana Skincare currently consists of a portfolio of 19 skin care products, most of which are based on potent extracts from plants found in New Zealand's unspoiled na...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch